Biogen Raises 2026 EPS Guidance Floor as Growth Portfolio Expands

Biogen raised the lower end of its full-year 2026 non-GAAP diluted earnings-per-share guidance after its Growth Portfolio expanded 49% in the third quarter, even as multiple sclerosis product revenue declined. The company now expects non-GAAP diluted EPS of $12.20 to $13.00 for 2026. It lifted the lower end from $12.00 and kept the upper end at $13.00. Revenue reached $2.804 billion, up 11% year over year. The Growth Portfolio generated $1.26 billion and drove double-digit revenue growth. The quarter included the first full quarter of Apellis products.

Source: TokenPost